Pivotal trial results for upadacitinib (Rinvoq) monotherapy in patients with active rheumatoid arthritis and an inadequate response to methotrexate were published on 2019-01-01. The study, known as SELECT-MONOTHERAPY, compared upadacitinib monotherapy to methotrexate monotherapy in this patient population.
Background
Upadacitinib was investigated as a monotherapy for adults with active rheumatoid arthritis. This patient population had previously shown an inadequate response to methotrexate, indicating a need for alternative treatment options.
Trial design
The SELECT-MONOTHERAPY study was a randomised, placebo-controlled trial. It evaluated upadacitinib as a monotherapy in adults diagnosed with active rheumatoid arthritis who had an inadequate response to methotrexate. The study compared upadacitinib monotherapy against methotrexate monotherapy.
What this means
The publication of these pivotal trial results makes the data from the SELECT-MONOTHERAPY study available for review by the scientific and medical communities. For clinicians, these findings contribute to the understanding of upadacitinib as a potential monotherapy option for patients with active rheumatoid arthritis who have not adequately responded to methotrexate. Researchers can utilize this published data to further evaluate the drug's profile and its implications for future treatment strategies in rheumatology.
Source
The information regarding these pivotal trial results was obtained from a publication indexed on PubMed. The article, titled "Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-con", was published on 2019-01-01 and is available via pubmed.ncbi.nlm.nih.gov.